ConductScience.org, home

Paper36914633

An anti-HER2 biparatopic antibody that induces unique HER2 clustering and complement-dependent cytotoxicity.

Weisser NE and 38 others. Nat Commun, 2023. Cited by 167 papers, by iCite.

Cite this record

ConductScience Library. An anti-HER2 biparatopic antibody that induces unique HER2 clustering and complement-dependent cytotoxicity. Papers, record 36914633. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/36914633

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
An anti-HER2 biparatopic antibody that induces unique HER2 clustering and complement-dependent cytotoxicity.
PubMed
Journal
Nat Commun
PubMed
Year
2023
PubMed
Publication types
Journal Article, Research Support, Non-U.S. Gov't
PubMed
Citations, by iCite
167
iCite
Relative citation ratio, by iCite
14.3
iCite
Revised in PubMed
2026-01-27
PubMed

Authors39

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Weisser NENina Ehttps://orcid.org/0000-0002-9903-2429
2Sanches MMariohttps://orcid.org/0000-0003-3488-2526
3Escobar-Cabrera EEric
4O'Toole JJason
5Whalen EElizabeth
6Chan PWYPeter W Y
7Wickman GGrant
8Abraham LLibin
9Choi KKatehttps://orcid.org/0000-0002-7959-1944
10Harbourne BBryant
11Samiotakis AAntonios
12Rojas AHAndrea Hernández
13Volkers GGesahttps://orcid.org/0000-0002-9901-0705
14Wong JJodi
15Atkinson CEClaire E
16Baardsnes JJason
17Worrall LJLiam J
18Browman DDuncan
19Smith EEEmma E
20Baichoo PPriya

Source PubMed

See all 39 authorsDownload CSV of authors

Topics10

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Antineoplastic AgentsMajor topic
Antibodies, BispecificMajor topic
Breast NeoplasmsMajor topic
Humans
Female
Xenograft Model Antitumor Assays
Cell Line, Tumor
Trastuzumab
Erb-b2 Receptor Tyrosine Kinases
Antibody-Dependent Cell Cytotoxicity

Source PubMed

Download CSV of topics

References73

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
120068220
A novel approach to preventing the hemolysis of paroxysmal nocturnal hemoglobinuria: both complement-mediated cytolysis and C3 deposition are blocked by a monoclonal antibody specific for the alternative pathway of complement.
Blood2010https://conductscience.org/library/papers/20068220PubMed
226249021Single molecule localization deep within thick cells; a novel super-resolution microscope.J Biophotonics2016https://conductscience.org/library/papers/26249021PubMed
327255951Intermolecular biparatopic trapping of ErbB2 prevents compensatory activation of PI3K/AKT via RAS-p110 crosstalk.Nat Commun2016https://conductscience.org/library/papers/27255951PubMed
411521719The basic biology of HER2.Ann Oncol2001https://conductscience.org/library/papers/11521719PubMed
522471661Intrinsic and acquired resistance to HER2-targeted therapies in HER2 gene-amplified breast cancer: mechanisms and clinical implications.Crit Rev Oncog2012https://conductscience.org/library/papers/22471661PubMed
68102322Differential responses of human tumor cell lines to anti-p185HER2 monoclonal antibodies.Cancer Immunol Immunother1993https://conductscience.org/library/papers/8102322PubMed
712393572In vitro mechanisms of action of rituximab on primary non-Hodgkin lymphomas.Blood2003https://conductscience.org/library/papers/12393572PubMed
824492309
HER2 monoclonal antibodies that do not interfere with receptor heterodimerization-mediated signaling induce effective internalization and represent valuable components for rational antibody-drug conjugate design.
MAbs2014https://conductscience.org/library/papers/24492309PubMed
920728210
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Lancet2010https://conductscience.org/library/papers/20728210PubMed
1022426455Anti-EGFR biparatopic-SEED antibody has enhanced combination-activity in a single molecule.Arch Biochem Biophys2012https://conductscience.org/library/papers/22426455PubMed
1112543813Anti-CD20 therapeutic antibody rituximab modifies the functional organization of rafts/microdomains of B lymphoma cells.Cancer Res2003https://conductscience.org/library/papers/12543813PubMed
1221559149Simultaneous multiple-emitter fitting for single molecule super-resolution imaging.Biomed Opt Express2011https://conductscience.org/library/papers/21559149PubMed
1310941909Comparison of in vitro antibody-targeted cytotoxicity using mouse, rat and human effectors.Cancer Immunol Immunother2000https://conductscience.org/library/papers/10941909PubMed
1428639341Rigidity of the extracellular part of HER2: Evidence from engineering subdomain interfaces and shared-helix DARPin-DARPin fusions.Protein Sci2017https://conductscience.org/library/papers/28639341PubMed
1510742152Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets.Nat Med2000https://conductscience.org/library/papers/10742152PubMed
1610692345Size-distribution analysis of macromolecules by sedimentation velocity ultracentrifugation and lamm equation modeling.Biophys J2000https://conductscience.org/library/papers/10692345PubMed
1727828362Real-time 3D stabilization of a super-resolution microscope using an electrically tunable lens.Opt Express2016https://conductscience.org/library/papers/27828362PubMed
1815490369Molecular approach to breast cancer treatment.Semin Oncol2004https://conductscience.org/library/papers/15490369PubMed
1920588256Statistical issues in longitudinal data analysis for treatment efficacy studies in the biomedical sciences.Mol Ther2010https://conductscience.org/library/papers/20588256PubMed
2015264254UCSF Chimera--a visualization system for exploratory research and analysis.J Comput Chem2004https://conductscience.org/library/papers/15264254PubMed

See all 73 referencesDownload CSV of references

Cited by123

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 167 citations.

PMIDTitleJournalYearIn PapersSource
42958443HER2 in solid tumors: microenvironment features and multifaceted advances from mechanisms to clinical translation.Exp Hematol Oncol2026https://conductscience.org/library/papers/42958443PubMed
42930033Complement in HER2-Positive Breast Cancer: A Conditionally Protective Mechanism Under Attack.Antibodies (Basel)2026https://conductscience.org/library/papers/42930033PubMed
42881857
Molecularly Guided Therapy and the Tumor Microenvironment in Advanced Cholangiocarcinoma: Current Evidence and Emerging Strategies Targeting FGFR2, HER2, and IDH1 with Pemigatinib, Zanidatamab, and Ivosidenib.
J Clin Med2026https://conductscience.org/library/papers/42881857PubMed
42878958A Meta-Analysis on Outcomes of Zanidatamab Plus Chemotherapy in Patients with Advanced HER2-positive Gastroesophageal Adenocarcinoma.J Gastrointest Cancer2026https://conductscience.org/library/papers/42878958PubMed
42860555Lactylation-Mediated HER2 Stabilization Promotes Trastuzumab Resistance in Gastric Cancer.Adv Sci (Weinh)2026https://conductscience.org/library/papers/42860555PubMed
42851488Biparatopic targeting of CD38 using CD38-specific trimeric antibody recruiters improves cytotoxicity against multiple myeloma.Front Immunol2026https://conductscience.org/library/papers/42851488PubMed
42850399Right-sizing treatment for HER2-positive breast cancer: evolving algorithms across the disease continuum.Nat Rev Clin Oncol2026https://conductscience.org/library/papers/42850399PubMed
42845595A shark variable new antigen receptor recognizes an occluded epitope of fibroblast activation protein.bioRxiv2026https://conductscience.org/library/papers/42845595PubMed
42835167Case Report: zanidatamab-based regimen as a potential later-line therapeutic option in HER2-amplified metastatic colorectal cancer.Front Pharmacol2026https://conductscience.org/library/papers/42835167PubMed
42780747Bispecific antibodies in gastrointestinal cancers: current applications and future perspectives.Front Oncol2026https://conductscience.org/library/papers/42780747PubMed
42776793Advances in Bispecific Antibodies and Antibody-Drug Conjugates for Colorectal Cancer Treatment.Antibodies (Basel)2026https://conductscience.org/library/papers/42776793PubMed
42773107Zanidatamab in patients with early stage HER2-positive breast cancer: the NeoZanHER phase 2 single-arm open-label trial.Nat Commun2026https://conductscience.org/library/papers/42773107PubMed
42703442Beyond trastuzumab: redefining first-line HER2-positive gastroesophageal cancer with bispecific HER2 targeting.J Gastrointest Oncol2026https://conductscience.org/library/papers/42703442PubMed
42688229Unlocking HER2 as a target in KRAS-mutated rectal cancer: a case of significant response to zanidatamab-based regimen.Front Immunol2026https://conductscience.org/library/papers/42688229PubMed
42653742Functional Characteristics Derived from the Structural Design of Bispecific Antibodies.Pharmaceuticals (Basel)2026https://conductscience.org/library/papers/42653742PubMed
42582644Therapeutics and toxicity management of human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer: a narrative review.Transl Breast Cancer Res2026https://conductscience.org/library/papers/42582644PubMed
42559290Antibody-Drug Conjugates and Peptide-Drug Conjugates: Current Understandings and Future Perspectives.MedComm (2020)2026https://conductscience.org/library/papers/42559290PubMed
42547622The next generation of antibody-drug conjugates.Nat Med2026https://conductscience.org/library/papers/42547622PubMed
42493602Advancing antibody drug conjugates in gastrointestinal cancers.Br J Cancer2026https://conductscience.org/library/papers/42493602PubMed
42463920Recent advances in function-enhanced antibody-drug conjugates: Antibody optimization and payload combination.Acta Pharmacol Sin2026https://conductscience.org/library/papers/42463920PubMed

See all 123 cited byDownload CSV of cited by

Genes18

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
AKT1207PubTator's text mininghttps://conductscience.org/library/genes/207NCBI Gene
C1QA712PubTator's text mininghttps://conductscience.org/library/genes/712NCBI Gene
C3718PubTator's text mininghttps://conductscience.org/library/genes/718NCBI Gene
CAT847PubTator's text mininghttps://conductscience.org/library/genes/847NCBI Gene
CD14929PubTator's text mininghttps://conductscience.org/library/genes/929NCBI Gene
CD37951PubTator's text mininghttps://conductscience.org/library/genes/951NCBI Gene
CSF11435PubTator's text mininghttps://conductscience.org/library/genes/1435NCBI Gene
EGF1950PubTator's text mininghttps://conductscience.org/library/genes/1950NCBI Gene
EGFR1956PubTator's text mininghttps://conductscience.org/library/genes/1956NCBI Gene
EIF2AK39451PubTator's text mininghttps://conductscience.org/library/genes/9451NCBI Gene
EPHB22048PubTator's text mininghttps://conductscience.org/library/genes/2048NCBI Gene
ERBB22064PubTator's text mininghttps://conductscience.org/library/genes/2064NCBI Gene
ERBB32065PubTator's text mininghttps://conductscience.org/library/genes/2065NCBI Gene
IL23558PubTator's text mininghttps://conductscience.org/library/genes/3558NCBI Gene
ITGAM3684PubTator's text mininghttps://conductscience.org/library/genes/3684NCBI Gene
KRT2054474PubTator's text mininghttps://conductscience.org/library/genes/54474NCBI Gene
RET5979PubTator's text mininghttps://conductscience.org/library/genes/5979NCBI Gene
SCFV652070PubTator's text mininghttps://conductscience.org/library/genes/652070NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/36914633

GET https://conductscience.org/api/papers/v1/36914633/authors?page=2